These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 37520563)

  • 21. Paclitaxel enhances antibody-dependent cell-mediated cytotoxicity of trastuzumab by rapid recruitment of natural killer cells in HER2-positive breast cancer.
    Miura D; Yoneyama K; Furuhata Y; Shimizu K
    J Nippon Med Sch; 2014; 81(4):211-20. PubMed ID: 25186575
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition.
    Di Modica M; Sfondrini L; Regondi V; Varchetta S; Oliviero B; Mariani G; Bianchi GV; Generali D; Balsari A; Triulzi T; Tagliabue E
    Oncotarget; 2016 Jan; 7(1):255-65. PubMed ID: 26595802
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monocytes and the 38kDa-antigen of mycobacterium tuberculosis modulate natural killer cell activity and their cytolysis directed against ovarian cancer cell lines.
    Gottschalk N; Lang S; Kimmig R; Singh M; Brandau S
    BMC Cancer; 2012 Oct; 12():451. PubMed ID: 23036052
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing.
    Kute TE; Savage L; Stehle JR; Kim-Shapiro JW; Blanks MJ; Wood J; Vaughn JP
    Cancer Immunol Immunother; 2009 Nov; 58(11):1887-96. PubMed ID: 19340424
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 3D tumor spheroid microarray for high-throughput, high-content natural killer cell-mediated cytotoxicity.
    Gopal S; Kwon SJ; Ku B; Lee DW; Kim J; Dordick JS
    Commun Biol; 2021 Jul; 4(1):893. PubMed ID: 34290356
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IFN-α augments natural killer-mediated antibody-dependent cellular cytotoxicity of HIV-1-infected autologous CD4+ T cells regardless of major histocompatibility complex class 1 downregulation.
    Tomescu C; Tebas P; Montaner LJ
    AIDS; 2017 Mar; 31(5):613-622. PubMed ID: 28225449
    [TBL] [Abstract][Full Text] [Related]  

  • 27. E-cadherin expression on human carcinoma cell affects trastuzumab-mediated antibody-dependent cellular cytotoxicity through killer cell lectin-like receptor G1 on natural killer cells.
    Yamauchi C; Fujii S; Kimura T; Kuwata T; Wada N; Mukai H; Matsumoto N; Fukayama M; Ochiai A
    Int J Cancer; 2011 May; 128(9):2125-37. PubMed ID: 21387286
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Engineering of CD34+ progenitor-derived natural killer cells with higher-affinity CD16a for enhanced antibody-dependent cellular cytotoxicity.
    van Hauten PMM; Hooijmaijers L; Vidal-Manrique M; van der Waart AB; Hobo W; Wu J; Blijlevens NMA; Jansen JH; Walcheck B; Schaap NPM; de Jonge PKJD; Dolstra H
    Cytotherapy; 2024 Mar; 26(3):252-260. PubMed ID: 38127030
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab.
    Fujii R; Friedman ER; Richards J; Tsang KY; Heery CR; Schlom J; Hodge JW
    Oncotarget; 2016 Jun; 7(23):33498-511. PubMed ID: 27172898
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds.
    Guti E; Bede ÁM; Váróczy C; Hegedűs C; Demény MÁ; Virág L
    J Vis Exp; 2023 Aug; (198):. PubMed ID: 37607075
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Natural Killer cells and monoclonal antibodies: Two partners for successful antibody dependent cytotoxicity against tumor cells.
    Gauthier M; Laroye C; Bensoussan D; Boura C; Decot V
    Crit Rev Oncol Hematol; 2021 Apr; 160():103261. PubMed ID: 33607229
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer.
    Desroys du Roure P; Lajoie L; Mallavialle A; Alcaraz LB; Mansouri H; Fenou L; Garambois V; Rubio L; David T; Coenon L; Boissière-Michot F; Chateau MC; Ngo G; Jarlier M; Villalba M; Martineau P; Laurent-Matha V; Roger P; Guiu S; Chardès T; Gros L; Liaudet-Coopman E
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38290768
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity.
    Peipp M; Derer S; Lohse S; Staudinger M; Klausz K; Valerius T; Gramatzki M; Kellner C
    Oncotarget; 2015 Oct; 6(31):32075-88. PubMed ID: 26392331
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy.
    Fantini M; Arlen PM; Tsang KY
    Front Immunol; 2023; 14():1275904. PubMed ID: 38077389
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery.
    Sturniolo I; Váróczy C; Bede ÁM; Hegedűs C; Demény MÁ; Virág L
    J Vis Exp; 2024 Apr; (206):. PubMed ID: 38738886
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In Vivo PET Imaging of
    Pham TT; Chenoweth A; Patel N; Banu A; Osborn G; Blower PJ; Karagiannis SN; Ma MT
    J Nucl Med; 2024 Jul; 65(7):1035-1042. PubMed ID: 38844362
    [TBL] [Abstract][Full Text] [Related]  

  • 37. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
    Wu L; Adams M; Carter T; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB
    Clin Cancer Res; 2008 Jul; 14(14):4650-7. PubMed ID: 18628480
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ADCC employing an NK cell line (haNK) expressing the high affinity CD16 allele with avelumab, an anti-PD-L1 antibody.
    Jochems C; Hodge JW; Fantini M; Tsang KY; Vandeveer AJ; Gulley JL; Schlom J
    Int J Cancer; 2017 Aug; 141(3):583-593. PubMed ID: 28477372
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.
    Luedke E; Jaime-Ramirez AC; Bhave N; Roda J; Choudhary MM; Kumar B; Teknos TN; Carson WE
    Surgery; 2012 Sep; 152(3):431-40. PubMed ID: 22770960
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2.
    Varchetta S; Gibelli N; Oliviero B; Nardini E; Gennari R; Gatti G; Silva LS; Villani L; Tagliabue E; Ménard S; Costa A; Fagnoni FF
    Cancer Res; 2007 Dec; 67(24):11991-9. PubMed ID: 18089830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.